Sign inJoin waitlistJoin the waitlist

Harlan Pinto

Associate Professor of Medicine (Oncology), Emeritus · Stanford Health Care

Credentials: · · · ·

History

Stanford University School of Medicine (1991) CA
1989–1991
Internal Medicine
Massachusetts General Hospital
1983–1984
Yale School of Medicine
1979–1983

Research

Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial
Journal of the National Cancer Institute · 2008 · 2,210 citations
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2020 · 1,128 citations
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018
Journal of the National Comprehensive Cancer Network · 2018 · 468 citations

Dimitrios Colevas
16 papers
Anthony Cmelak
13 papers
Bharat Mittal
12 papers
David Brizel
12 papers
David Pfister
12 papers
EM
Ellie Maghami
12 papers · 1 as a fellow
Jatin Shah
12 papers
MG
Maura Gillison
12 papers
Sharon Spencer
12 papers
Wesley Hicks
12 papers
Willard Fee
12 papers
David Eisele
11 papers

Grants

Tumor Hypoxia: Molecular Studies and Clinical Exploitation
National Cancer Institute · P01
Project lead · $855.5K · Stanford University
1997–2001
Center for Advanced Magnetic Resonance Technology at Stanford
National Center for Research Resources · P41
Project lead · Stanford University
1999–2000

Clinical trials

Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Study chair · Completed · Phase 2
Stanford University
1996–2005
Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer
Study chair · Completed · Phase 2
Eastern Cooperative Oncology Group
1995
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2029
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2032